Cortexin in rat seizure models: nanoparticle nasal delivery and a neutral acute result
V. A. Aniol, Yu. Novitskaia, T. N. Borodina, T. V. Bukreeva, N. A. Lazareva, Yu. V. Moiseeva, M. V. Onufriev, M. Yu. Stepanichev, A. A. Iakovlev, A. B. Gekht, O. K. Granstrem, N. V. Guliaeva · 2011 · Zh Nevrol Psikhiatr Im S S Korsakova. 2011;111(12):68–73. PMID 22433813
Reported findings and study design
Narrative findings; numerical extraction incomplete
Acute and chronic rat seizure models; intraperitoneal solution or intranasal nanoparticle Cortexin. Group sizes and route-specific outcomes not supplied.
Dose, route and schedule
Abstract lists 0.015, 0.15 and 1.0 mg/kg; intraperitoneal solution or intranasal nanoparticle complex. Route-specific schedules and dose assignments are not resolved by the abstract.
Protocol source ↗ · Original indexed abstract; no route-specific numerical table
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Acute status model | No effect on convulsions after long-term pretreatment described | |
| Chronic model | Dose-dependent antiepileptic effect described; no numerical magnitude supplied | |
| Dose and formulation | 0.015, 0.15 and 1.0 mg/kg; intraperitoneal solution or intranasal nanoparticle complex | No fully resolved route-specific schedule or dose–outcome table in the abstract |
Positive and neutral model results coexist. The nanoparticle nasal formulation cannot be equated with an ordinary nasal solution or with PPK-V. No human absorption or safety conclusion follows.
Source for the extracted data ↗ · Checked 2026-11-08
Molekul summary of the linked publication. Educational information, not medical advice. Seek qualified healthcare help for medical conditions.
Methods, limitations & source review
Study limitations
- Group sizes, route-specific effect sizes, dosing frequency, pretreatment duration and adverse-event counts unavailable in the checked abstract.
- The abstract pools discussion of intraperitoneal solution and intranasal nanoparticle preparations; it does not establish which dose produced which route-specific outcome.
- A seizure model does not establish improved athletic performance, human nasal bioavailability or PPK-V efficacy.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Document format: Original indexed abstract
Review depth: Indexed abstract only; full methods, route-specific tables and sample sizes not recovered
Source access and review scope
Original indexed abstract checked. Nasal delivery used a nanoparticle preparation; no inference of equivalent absorption from an ordinary nasal solution.
Recorded source-check date: 2026-11-08. This date does not imply a completed systematic review.
Source type: Original animal journal research
Citation and original source
Original source: V. A. Aniol, Yu. Novitskaia, T. N. Borodina, T. V. Bukreeva, N. A. Lazareva, Yu. V. Moiseeva, M. V. Onufriev, M. Yu. Stepanichev, A. A. Iakovlev, A. B. Gekht, O. K. Granstrem, N. V. Guliaeva. Cortexin in rat seizure models: nanoparticle nasal delivery and a neutral acute result Zh Nevrol Psikhiatr Im S S Korsakova. 2011;111(12):68–73. PMID 22433813 2011.
Molekul research summary: https://molekul.io/research/cortexin-nanoparticle-seizures-2011. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry